Levetiracetam as a Primary Agent?

Event Time

Original Date - Friday, September 9 8:30 AM - 9:00 AM Central Time (US & Canada)

Info Alert

Create or Log in to My Show Planner to see Videos and Resources.

Videos

Resources

Create or Log in to My Show Planner to see Videos and Resources.


{{chatHeaderContent}}

{{chatBodyContent}}

Resources

Create or Log in to My Show Planner to see Videos and Resources.


Info Alert

This Session Has Not Started Yet

Be sure to come back after the session starts to have access to session resources.

Event Location

Location: 214CD


Event Information

Presentation Code: 361.2

Title: Levetiracetam as a Primary Agent?

Description:

On-demand access available through October 11th, 2022. 

Epilepsy is the most common neurologic disorder in the canine patient. Management of epilepsy is often complicated by availability of effective antiepileptic drugs (AED). Historically, first generation antiepileptic drugs such as phenobarbital and potassium bromide have been used as monotherapy to treat epilepsy due to availability and relative efficacy. However, second generation antiepileptic drugs like levetiracetam are gaining in popularity, but there is a paucity of information regarding efficacy as a monotherapy. The purpose of this session is to review the efficacy of levetiracetam as a primary agent.    

Presentation Code: 361.2

Type: Live Streamed Lecture

Presentation Level: VECCSpert


Speakers


Tracks


Education Units

  • Medical – 0.5 Units